Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Inmagene Approved to Start Phase I Trial of Novel BTK Inhibitor

publication date: May 20, 2022

Inmagene, a Shanghai- Diego biopharma, was approved to start a Phase I US trial of its third-gen BTK inhibitor. The company describes IMG-004 as a highly selective and brain permeable non-covalent, reversible small molecule inhibitor for inflammatory/autoimmune diseases that require long-term treatment. IMG-004 is one of four novel pre-clinical immunological candidates that Inmagene in-licensed from HutchMed last year in a deal worth up to $920 million. BTK, a non-receptor intracytoplasmic tyrosine kinase, is involved in the innate and adaptive immune responses of specific immune-mediated diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital